CUSTOMIZE: Implementation-Effectiveness Study of Long-Acting Cabotegravir and Rilpivirine Injection in US Healthcare Settings

July 18-21, 2021; Virtual
In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 21, 2022

Clinical Care Options (CCO) downloadable slides from Cristina Mussini, MD, providing practical insights into implementing long-acting ART into HIV care

Babafemi Taiwo, MBBS
Program Director
Cristina Mussini, MD
Released: June 14, 2022

Clinical Care Options (CCO) downloadable slides from Dr Darrell Tan, providing an overview of available long-acting ART for HIV treatment and prevention

Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Released: June 14, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: May 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings